Clinical Significance of MYT1L Gene Polymorphisms in Chinese Patients with Gastric Cancer

• Yangmei Zhang ,

  Contributed equally to this work with: Yangmei Zhang, Haixia Zhu, Xunlei Zhang

  Affiliations Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China, Department of Oncology, Xuzhou Central Hospital, Affiliated Xuzhou Hospital, College of Medicine, Southeast University, Xuzhou, Nanjing

  ⨯
• Haixia Zhu ,

  Contributed equally to this work with: Yangmei Zhang, Haixia Zhu, Xunlei Zhang

  Affiliations Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China, Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China

  ⨯
• Xunlei Zhang ,

  Contributed equally to this work with: Yangmei Zhang, Haixia Zhu, Xunlei Zhang

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Dongying Gu,

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Xichang Zhou,

  Affiliation Department of Imaging and Nuclear Medicine, Affiliated Hospital of Qinghai University, Medical College of Qinghai University, XiNing, China

  ⨯
• Meilin Wang,

  Affiliations Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China, Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China

  ⨯
• Chunxiang Cao,

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Xiaojing Zhang,

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Xiaomin Wu,

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Weida Gong,

  Affiliation Department of Surgery, Yixing Cancer Hospital, Yixing, China

  ⨯
• Yongfei Tang,

  Affiliation Department of Surgery, Yixing People's Hospital, Yixing, China

  ⨯
• Jianwei Zhou,

  Affiliation Department of Molecular Cell Biology and Toxicology, School of Public Health, Cancer Center, Nanjing Medical University, Nanjing, China

  ⨯
• Cuiju Tang ,

  * E-mail: cuijutang@sina.com (CT); drzhengdongzhang@sina.com (ZZ); njjinfeichen@sina.com (JC)

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯
• Zhengdong Zhang ,

  * E-mail: cuijutang@sina.com (CT); drzhengdongzhang@sina.com (ZZ); njjinfeichen@sina.com (JC)

  Affiliations Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China, Department of Genetic Toxicology, the Key Laboratory of Modern Toxicology of Ministry of Education, School of Public Health, Nanjing Medical University, Nanjing, China

  ⨯
• Jinfei Chen

  * E-mail: cuijutang@sina.com (CT); drzhengdongzhang@sina.com (ZZ); njjinfeichen@sina.com (JC)

  Affiliation Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China

  ⨯